PBPIA
ITRM

Pivotal bioVenture Partners Investment Advisor’s Iterum Therapeutics ITRM Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-63,006
Closed -$935K – 10
2020
Q4 		$935K Buy
+63,006
New +$737K 0.31% 9

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's ITRM Position: Q1 2021 in Review

Pivotal bioVenture Partners Investment Advisor sold out of Iterum Therapeutics (ITRM) in Q1 2021, closing a stake of 63,006 shares — an estimated $935K sold.

Pivotal bioVenture Partners Investment Advisor first reported a position in ITRM in Q4 2020 and held it in 1 quarter. The position peaked at $935K in Q4 2020. 50 funds tracked by Wall St. Rank hold ITRM as of Q1 2021.

  • Pivotal bioVenture Partners Investment Advisor reported no remaining Iterum Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Pivotal bioVenture Partners Investment Advisor sold 63,006 Iterum Therapeutics shares in Q1 2021, an estimated $935K.
  • Pivotal bioVenture Partners Investment Advisor first reported a position in Iterum Therapeutics in Q4 2020 and held it in 1 quarter.
  • Pivotal bioVenture Partners Investment Advisor's Iterum Therapeutics position peaked at $935K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2021.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2021, filed 14 May 2021.